Pharmacokinetics of Ferumoxytol in the Abdomen and Pelvis: A Dosing Study with 1.5- and 3.0-T MRI Relaxometry.

Radiology

Form the Departments of Radiology (S.A.W., T.S., U.M., S.D.S., C.A.C., S.K., D.H., S.B.R.), Biostatistics and Medical Informatics (K.M.W.), Biomedical Engineering (S.B.R.), Medical Physics (S.B.R.), Medicine (S.B.R.), and Emergency Medicine (S.B.R.), University of Wisconsin-Madison, University of Wisconsin School of Medicine and Public Health, 600 Highland Ave, E3/366, Madison, WI 53792; Clinic of Radiology and Nuclear Medicine, Basel University Hospital, Basel, Switzerland (T.S.); Department of Radiology, University of Yamanashi, Yamanashi, Japan (U.M.); and Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Germany (S.K.).

Published: January 2020

Background The off-label use of ferumoxytol (FE), an intravenous iron preparation for iron deficiency anemia, as a contrast agent for MRI is increasing; therefore, it is critical to understand its pharmacokinetics. Purpose To evaluate the pharmacokinetics of FE in the abdomen and pelvis, as assessed with quantitative 1.5- and 3.0-T MRI relaxometry. Materials and Methods R2*, an MRI technique used to estimate tissue iron content in the abdomen and pelvis, was performed at 1.5 and 3.0 T in 12 healthy volunteers between April 2015 and January 2016. Volunteers were randomly assigned to receive an FE dose of 2 mg per kilogram of body weight (FE) or 4 mg/kg (FE). MRI was repeated at 1.5 and 3.0 T for each volunteer at five time points: days 1, 2, 4, 7, and 30. A radiologist experienced in MRI relaxometry measured R2* in organs of the mononuclear phagocyte system (MPS) (ie, liver, spleen, and bone marrow), non-MPS anatomy (kidney, pancreas, and muscle), inguinal lymph nodes (LNs), and blood pool. A paired Student test was used to compare changes in tissue R2*. Results Volunteers (six female; mean age, 44.3 years ± 12.2 [standard deviation]) received either FE ( = 5) or FE ( = 6). Overall R2* trend analysis was temporally significant ( < .001). Time to peak R2* in the MPS occurred on day 1 for FE and between days 1 and 4 for FE ( < .001 to < .002). Time to peak R2* in non-MPS anatomy, LNs, and blood pool occurred on day 1 for both doses ( < .001 to < .09). Except for the spleen (at 1.5 T) and liver, MPS R2* remained elevated through day 30 for both doses ( = .02 to = .03). Except for the kidney and pancreas, non-MPS, LN, and blood pool R2* returned to baseline levels between days 2 and 4 at FE ( = .06 to = .49) and between days 4 and 7 at FE ( = .06 to = .63). There was no difference in R2* change between non-MPS and LN R2* at any time (range, 1-71 sec vs 0-50 sec; = .06 to = .97). Conclusion The pharmacokinetics of ferumoxytol in lymph nodes are distinct from those in mononuclear phagocyte system (MPS) organs, parallel non-MPS anatomy, and the blood pool. © RSNA, 2019

Download full-text PDF

Source
http://dx.doi.org/10.1148/radiol.2019190489DOI Listing

Publication Analysis

Top Keywords

blood pool
16
abdomen pelvis
12
mri relaxometry
12
non-mps anatomy
12
r2*
10
pharmacokinetics ferumoxytol
8
15- 30-t
8
30-t mri
8
mononuclear phagocyte
8
phagocyte system
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!